文献速递瓣膜病与结构性心脏病血脂与心血管预防

PRMT3介导的精氨酸甲基化稳定PCSK9促进主动脉瓣钙化

PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification.
PubMed 文献 · Circulation · 2026-03-09

本研究探讨PRMT3在主动脉瓣钙化中的作用及机制,利用患者瓣膜组织和细胞、高胆固醇饮食ApoE-/-小鼠及药物干预,发现PRMT3表达上调,通过甲基化PCSK9 R582阻止CHIP结合并延长PCSK9半衰期,从而促进钙化。

要点

  • PRMT3在钙化主动脉瓣中表达上调,由RUNX2招募P300通过H3K27ac促进其转录。
  • Prmt3单倍不足或药物抑制/降解PRMT3可减轻ApoE-/-小鼠主动脉瓣钙化并改善超声指标。
  • PRMT3催化PCSK9 R582不对称二甲基化,阻止CHIP结合K575,抑制泛素化降解,稳定PCSK9。

核心结论

  • PRMT3介导的精氨酸甲基化稳定PCSK9,促进主动脉瓣钙化,为钙化性主动脉瓣疾病提供新的翻译后调控机制。

研究设计与样本

  • 使用患者主动脉瓣叶和瓣膜间质细胞评估PRMT3表达及机制。
  • 采用高胆固醇饮食喂养的ApoE-/-小鼠及Prmt3单倍不足模型。
  • 在体内研究PRMT3抑制剂SGC707和PROTAC化合物11对主动脉瓣钙化的影响。

主要发现

  • PRMT3在主动脉瓣钙化过程中表达显著上调。
  • Prmt3单倍不足减轻高胆固醇饮食ApoE-/-小鼠主动脉瓣钙化,表现为瓣叶厚度和钙沉积减少、峰值跨瓣流速降低、平均跨瓣压差减小、主动脉瓣面积增加、骨源性标志物OPN和Osx水平降低。
  • 药物抑制PRMT3(SGC707)和PROTAC介导的PRMT3降解均产生抗钙化效果。
  • PRMT3通过酶活性促进人瓣膜间质细胞成骨分化,并催化PCSK9 R582不对称二甲基化,延长PCSK9半衰期,阻止CHIP与PCSK9 K575结合,抑制泛素化降解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortic valve calcification increases leaflet stiffness and contributes to the development of calcific aortic valve disease. The molecular and cellular mechanisms underlying calcification remain unclear. Here, we aimed to investigate the role of PRMT3 (protein arginine methyltransferase 3) in valvular calcification and calcific aortic valve disease progression. METHODS: Both aortic valve leaflets and valvular interstitial cells from patients were used to evaluate the expression pattern and investigate the underlying mechanism of PRMT3 in calcific aortic valve disease pathogenesis. High-cholesterol diet-fed Apoe (apolipoprotein E)-deficient (ApoE-/-) mice with Prmt3 haploinsufficiency were used to examine the role of PRMT3 in aortic valve calcification. The effects of PRMT3 inhibition (SGC707) and degradation (PROTAC compound 11) on aortic valve calcification were investigated in vivo. To elucidate the mechanisms underlying the procalcific effects of PRMT3, we performed immunoprecipitation coupled with liquid chromatography-tandem mass spectrometry and coimmunoprecipitation assays with an enzymatically inactive PRMT3 variant as well as arginine-to-lysine and lysine-to-alanine substitution PCSK9 variants. RESULTS: We found that PRMT3 expression was significantly upregulated during aortic valve calcification. RUNX2 (runt-related transcription factor 2) recruited P300 to promote PRMT3 expression through histone H3 lysine 27 acetylation. Moreover, Prmt3 haploinsufficiency markedly ameliorated aortic valve calcification in high-cholesterol diet-fed ApoE-/- mice, as revealed by reduced thickness and calcium deposition in the aortic valve leaflets, improved echocardiographic measures (decreased peak transvalvular jet velocity, reduced mean transvalvular pressure gradient, and increased aortic valve area), and decreased levels of osteogenic markers OPN (osteopontin) and Osx (Osterix) in the aortic valve leaflets. In addition, anticalcific effects were achieved through pharmacologic PRMT3 inhibition with SGC707 and PRMT3 degradation through PROTAC. Consistent with the in vivo results, we found that PRMT3 promoted the osteogenic differentiation of human valvular interstitial cells through its enzymatic activity. Mechanistically, we revealed that PRMT3 catalyzed the asymmetric dimethylation of PCSK9 at the arginine 582 residue (R582), which was accompanied by a prolonged PCSK9 half-life. This methylation prevented the binding of the E3 ligase CHIP (carboxyl terminus of Hsc70-interacting protein) to PCSK9 at lysine 575 (K575), thereby abrogating ubiquitination-mediated degradation of PCSK9, which is a procalcific factor, and accelerating aortic valve calcification progression. CONCLUSIONS: We identify a previously unrecognized posttranslational mechanism regulating PCSK9 stability in valve interstitial cells during calcific aortic valve disease and establish a link between PRMT3-mediated arginine methylation and valve-specific lipid-osteogenic coupling.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zhang X, Hao Y, Han D, et al. PRMT3-Mediated Arginine Methylation Stabilizes PCSK9 to Promote Aortic Valve Calcification. Circulation. 2026. PMID: 41797709. doi:10.1161/CIRCULATIONAHA.125.078830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。